Intrauterine anti-adhesion gel as well as preparation method and application thereof

By using uterine cavity anti-adhesion gel with a combination of polyethylene glycol polymers with active ester and amino polymers, the problems of high recurrence rate and unstable efficacy of existing treatment methods are solved, and a safe and stable uterine system is achieved. Caval adhesion prevention reduces the risk of uterine adhesion and gradually degrades in the uterus without harm.

CN118892585APending Publication Date: 2024-11-05JIANGSU DEVICELAND MEDICAL INSTR CORP LTD +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410907580.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing methods for treating uterine adhesions have high recurrence rates, unstable efficacy and risk of endometrial damage, and lack safe, stable, and good biocompatible anti-adhesion gels.

Method used

Using a combination of polyethylene glycol polymers with active esters and amino polymers to form an uterine cavity anti-adhesion gel, a three-dimensional network structure is constructed through cross-linking, providing toughness and viscosity, and gradually degradation in the uterus .

Benefits of technology

The gel adheres in the uterine cavity without falling off, prevents adhesions, reduces the incidence of uterine cavity adhesions, is simple to operate, has good biocompatibility, is non-toxic and harmless, is safe and reliable, and does not cause compression damage to the inner wall of the uterine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892585A_ABST
    Figure CN118892585A_ABST
Patent Text Reader

Abstract

The invention relates to uterine cavity anti-adhesion gel as well as a preparation method and application thereof, and relates to the technical field of biological medicines, and the raw materials of the gel comprise a polyethylene glycol high-molecular polymer with active ester and an amino high-molecular polymer. The raw materials for preparing the hydrogel are simple, easy to obtain, safe and good in biocompatibility; the prepared hydrogel is good in toughness and viscosity, can be adhered to the inner surface of the uterine cavity when acting on the wound surface of the uterine cavity, and cannot fall off; the prepared hydrogel is soft, the shape of the hydrogel is adaptive to the shape of a cavity to change, and damage such as compression to the inner wall of the uterus is avoided; the prepared hydrogel is attached to the inner wall of the uterus by physically isolating the uterus in the healing process of the wound of the uterus, so that the situation of intrauterine adhesion is fundamentally prevented, and the occurrence rate of intrauterine adhesion is reduced; and the hydrogel can gradually become a flowable aqueous solution in vivo within 4-7 days and is discharged out of the body.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to an anti-uterine adhesion gel and a preparation method and application thereof. Background Art

[0002] Intrauterine adhesions (IUA), also known as Asherman syndrome, is a common gynecological disease of endometrial repair disorder in clinical practice. The cause of the disease is endometrial damage caused by infection, trauma after uterine surgery, etc. The damaged endometrium causes the uterine cavity and / or cervix to be completely or partially closed due to fibrous adhesions, leading to decreased menstrual volume, amenorrhea, cyclical lower abdominal pain, secondary infertility, recurrent miscarriage, etc. Some IUA patients with successful pregnancies may even experience symptoms such as placenta adhesion, placenta implantation, and premature birth. These clinical symptoms seriously affect the menstrual status and fertility needs of women of childbearing age.

[0003] Conventional treatment methods include hysteroscopic intrauterine adhesion separation, placement of intrauterine contraceptive device, balloon or postoperative hormone, anti-adhesion drug treatment. However, hysteroscopic intrauterine adhesion separation, placement of intrauterine contraceptive device or balloon, etc., have a high postoperative recurrence rate and a high risk of postoperative endometrial damage. Oral estrogen, tamoxifen, aspirin, subcutaneous injection of gonadotropin-releasing hormone agonist and intrauterine injection of low-dose human chorionic gonadotropin and other drug treatments have unstable efficacy and long treatment cycles. In view of this, the present invention provides a uterine cavity anti-adhesion gel and its preparation method and application. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a uterine cavity anti-adhesion gel and its preparation method and application. The purpose is to provide a safe, stable, biocompatible, non-toxic and harmless degradation product, safe and reliable anti-adhesion gel.

[0005] The technical solution of the present invention to solve the above technical problems is as follows: In a first aspect, a uterine cavity anti-adhesion gel is provided, wherein the raw materials of the gel include: polyethylene glycol polymer with active ester and amino polymer, and the mass ratio of the polyethylene glycol polymer with active ester to the amino polymer is 1:(0.2-20).

[0006] The beneficial effects of the present invention are: (1) The raw materials used to prepare the gel of the present invention are simple, easy to obtain, safe and biocompatible.

[0007] (2) The hydrogel prepared by the present invention has good toughness and good viscosity. When acting on the uterine cavity wound, it will adhere to the inner surface of the uterine cavity and will not fall off; the hydrogel is soft and its shape changes adaptively according to the shape of the cavity, and will not cause damage such as compression to the inner wall of the uterus; during the healing process of the uterine wound, the hydrogel physically isolates the inner wall of the uterus, fundamentally preventing the occurrence of uterine adhesions and reducing the incidence of uterine adhesions.

[0008] (3) The hydrogel of the present invention will gradually turn into a fluid aqueous solution within 4-7 days in the body and be excreted from the body.

[0009] Furthermore, the gel is a three-dimensional network structure formed by cross-linking the polyethylene glycol high molecular polymer with active ester and the amino high molecular polymer.

[0010] Furthermore, the solid content of the gel is 1wt%-30wt%.

[0011] The beneficial effect of adopting the above further scheme is that the hydrogel within this range has good adhesion and continuity.

[0012] Furthermore, the polyethylene glycol high molecular polymer with active ester includes at least one of two-arm polyethylene glycol, four-arm polyethylene glycol and eight-arm polyethylene glycol.

[0013] The beneficial effect of adopting the above further scheme is that the polyethylene glycol with multiple arms and active esters is used to form a three-dimensional structure with a higher degree of cross-linking and better continuity when it reacts with the amino high molecular polymer.

[0014] Furthermore, the amino polymer includes at least one of gelatin (derived from animal skin, bone or tendon), polypeptide, chitosan, carboxymethyl chitosan, polyethylene imine and branched polyethylene imine, preferably one or two of branched polyethylene imine, gelatin and carboxymethyl chitosan.

[0015] The beneficial effect of adopting the above further scheme is that the amino polymer is degradable and can react with the polyethylene glycol polymer with active ester at room temperature.

[0016] In a second aspect, a method for preparing an intrauterine anti-adhesion gel comprises the following steps: dissolving a polyethylene glycol high molecular polymer with active ester in a solvent to obtain component A; dissolving an amino high molecular polymer in a solvent to obtain component B; and mixing the component A and the component B.

[0017] The beneficial effects of adopting the above scheme are: the preparation method of the intrauterine anti-adhesion gel of the present invention is simple and stable to operate, plays an auxiliary role in the self-repair process of the human body, and has no unknown side effects in drug use.

[0018] Furthermore, the polyethylene glycol polymer with active ester is dissolved in a solvent or the amino polymer is dissolved in a solvent by stirring and dissolving. Specifically, the stirring and dissolving method is at least one of stirring and dissolving at room temperature, stirring and dissolving at 40-70°C, mechanical stirring and dissolving, vortex mixing and dissolving, and ultrasonic dissolving; preferably, at least one of stirring and dissolving at room temperature, stirring and dissolving at 40-70°C, and vortex mixing and dissolving.

[0019] Furthermore, the solvent in component A is at least one of double distilled water, ultrapure water, deionized water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution; the solvent in component B is at least one of double distilled water, ultrapure water, deionized water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution.

[0020] Furthermore, the mass concentration of the polyethylene glycol high molecular polymer with active ester in the component A is 0.1wt%-20wt%; the mass concentration of the amino high molecular polymer in the component B is 0.01wt%-30wt%; and the volume ratio of the component A to the component B is 1:1-5.

[0021] The beneficial effect of adopting the above further scheme is that the polyethylene glycol high molecular polymer with active ester and the amino high molecular polymer are moderately cross-linked at a specific concentration to construct a hydrogel with both adhesion and continuous fluidity.

[0022] Furthermore, the mass concentration of the polyethylene glycol high molecular polymer with active ester in the component A is 0.5wt%-15wt%; the mass concentration of the amino high molecular polymer in the component B is 0.05wt%-10wt%.

[0023] A third aspect is the use of the intrauterine anti-adhesion gel in the preparation of products for preventing intrauterine adhesions.

[0024] When the intrauterine anti-adhesion hydrogel is used, after each component is fully mixed in the syringe, the hydrogel is injected into the uterine cavity through the syringe extension tube. The hydrogel adheres to the surface of the uterine cavity wall and achieves the effect of anti-adhesion by isolating the contact of the uterine cavity wall wound surface. Specifically, after the intrauterine surgery is completed, the fluid gel precursor (the mixture of the component A and the component B before cross-linking) is injected into the uterine cavity by a syringe, and the injection is easily performed through a narrow needle to avoid the patient from feeling pain and discomfort when passing through the narrow neck opening; the precursor injected into the uterine cavity forms a flexible gel state at body temperature, which can support the mechanical matrix of the uterine cavity and adjust its own shape according to the different shapes and sizes of the uterine cavity; after being injected into the uterine cavity, a cross-linking reaction occurs within 30 minutes to form an anti-adhesion gel. Since the hydrogel formed by the cross-linking reaction is formed by the reaction between the active ester and the amino group to form a new amino-active ester, the formed amino-active ester slowly degrades in the uterine cavity, and finally gradually changes from the anti-adhesion gel state to a fluid liquid, and is naturally discharged from the body in accordance with physiological conditions. This phase-transition adaptive intrauterine anti-adhesion fluid can regulate cell behavior through stress relaxation and help integrate biological signals to promote tissue regeneration, filling the gap in domestic medical devices in the field of intrauterine anti-adhesion medicine.

[0025] Furthermore, the intrauterine anti-adhesion hydrogel is used to prepare the anti-adhesion hydrogel in the uterine cavity of animals such as humans, mammals, birds, and reptiles. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is the hydrogel prepared in Example 1 of the present invention, wherein a is a state diagram after gelation, and b is a state diagram after being sucked up by a dropper after gelation, and the color in the diagram is the state after being dyed with brilliant green.

[0027] Figure 2 This is a graph showing the degradation results of the hydrogel prepared in Example 1 of the present invention when injected into the uterine cavity of SD rats.

[0028] Figure 3 The scanning electron microscope images of Example 1 and Example 6 after freeze-drying of the present invention are shown.

[0029] Figure 4 These are H&E sections of the contact tissues at different time periods after the hydrogel of Example 1 of the present invention was injected into the uterine cavity of SD rats.

[0030] Figure 5 This is a shear viscosity curve of the hydrogel according to Example 1 of the present invention as the shear rate changes, and the control example is deionized water.

[0031] Figure 6 The cytotoxicity of the hydrogel of Example 1 of the present invention after being incubated in extracts of different concentrations for 24 h and 48 h, respectively.

[0032] Figure 7 This is the degradation cycle of Example 1 of the present invention in a PBS solution at 37° C. in vitro. DETAILED DESCRIPTION

[0033] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0034] Description of the materials used in the following test examples: Two-arm polyethylene glycol (2arm-PEG-SG), four-arm polyethylene glycol (4arm-PEG-SG), 4arm-PEG-SC, 4arm-PEG-SS and eight-arm polyethylene glycol (8arm-PEG-SG) were purchased from Xiamen Sinobond Biotechnology; gelatin (derived from animal skin, bone or tendon) was purchased from Sigma; peptides were purchased from Aladdin; chitosan was purchased from McLean; carboxymethyl chitosan was purchased from Hydefeng Biotechnology; polyethyleneimine was purchased from McLean; branched polyethyleneimine was purchased from McLean; rats were purchased from Spaif (Beijing) Biotechnology Co., Ltd.; L929 cell line was from the Institute of Basic Medicine, Chinese Academy of Medical Sciences, Beijing.

[0035] Example 1 The present embodiment relates to a method for preparing an intrauterine adhesion-preventing gel, comprising the following steps: accurately weighing 23 mg of polyethylene glycol active ester (4arm-PEG-SG) in a centrifuge tube, adding 2.13 g of deionized water to dissolve, and recording as component A; accurately weighing 0.20 g of chitosan derivative in a sample bottle, adding 9.80 g of deionized water, stirring and dissolving at 50-60°C, and marking as component B. Take two syringes, draw 1.0 mL of component A and component B respectively into the centrifuge tube, shake and mix thoroughly, and the anti-intrauterine adhesion hydrogel can be obtained within 15-30 minutes at room temperature. The hydrogel prepared in this embodiment is as follows Figure 1 As shown, Figure 1 The samples in the image were stained with brilliant green.

[0036] Example 2 This embodiment relates to a method for preparing a gel for preventing intrauterine adhesion, comprising the following steps: accurately weighing 0.10g of polyethylene glycol active ester (2arm-PEG-SG) in a sample bottle, adding 4.90g of deionized water to fully dissolve the polyethylene glycol, and marking it as component A; accurately weighing 1.50g of gelatin in a sample bottle, adding 8.50g of deionized water, stirring and dissolving at 50-60°C, and marking it as component B. Take two 1.0mL syringes, draw 0.5mL of component A and 0.5mL of component B, or 0.5mL of component A and 1.0mL of component B in two syringes, and fully mix the two components through the two channels of the syringes overnight to obtain the hydrogel for preventing and treating intrauterine adhesion.

[0037] Example 3 This embodiment relates to a method for preparing an intrauterine adhesion prevention gel, comprising the following steps: accurately weighing 0.10g of polyethylene glycol active ester (8arm-PEG-SG) in a sample bottle, adding 4.90g of deionized water to fully dissolve the polyethylene glycol, and marking it as component A; accurately weighing 0.20g of chitosan derivative in a sample bottle, adding 9.80g of deionized water, or accurately weighing 0.10g of chitosan derivative in a sample bottle, adding 9.90g of deionized water, stirring and dissolving at 50°C-60°C, and marking it as component B. Take two 2.0mL syringes, draw 1mL of component A and 1.5mL of component B respectively, and fully mix the two components through the two channels of the syringe for 10-30min to obtain the anti-intrauterine adhesion hydrogel.

[0038] Example 4 The present embodiment relates to a method for preparing an intrauterine adhesion prevention gel, comprising the following steps: accurately weighing 0.10 g of polyethylene glycol active ester (4arm-PEG-SG) in a sample bottle, adding 3.20 g of deionized water, vortexing to fully dissolve the polyethylene glycol, and marking it as component A; accurately weighing 0.10 g of a PEI aqueous solution with a mass concentration of 50 wt% in a sample bottle, adding 9.90 g of deionized water, mixing, dispersing, and shaking for standby use. Take two 2.0 mL syringes, draw 1.0 mL of component A and 1.0 mL of component B respectively, and fully mix the two components through the two channels of the syringe to obtain the intrauterine adhesion prevention hydrogel within 1 min.

[0039] Example 5 The present embodiment relates to a method for preparing an intrauterine anti-adhesion gel, comprising the following steps: accurately weighing 0.10g of polyethylene glycol active ester (2arm-PEG-SG) in a sample bottle, adding 3.99g of deionized water, vortexing and mixing to fully dissolve the polyethylene glycol, and marking it as component A; accurately weighing 0.09g of a PEI aqueous solution with a mass concentration of 50wt% in a sample bottle, adding 9.90g of deionized water, mixing and dispersing, shaking, and setting aside, marking it as B1; accurately weighing 0.15g of a chitosan derivative in a sample bottle, adding 9.89g of deionized water, stirring and dissolving at 50℃-60℃, and marking it as component B2. Component B1 and component B2 are mixed evenly in a ratio of 1:3 (v:v) and marked as component C. Take two 2.0mL syringes, draw 1.0mL of component A and 2.0mL of component C respectively, and fully mix the two components through the two channels of the syringe to obtain the anti-intrauterine adhesion hydrogel within 15-30min.

[0040] Example 6 The present embodiment relates to a method for preparing an intrauterine anti-adhesion gel. The difference between the present embodiment and embodiment 1 is that 1.0 mL of component A and component B are respectively drawn into two syringes, and the two components are mixed evenly in the syringes through the two-way head of the syringes.

[0041] Example 7 This embodiment relates to a method for preparing an intrauterine anti-adhesion gel. The difference between this embodiment and Example 1 is that 4arm-PEG-SG is replaced by 4arm-PEG-SS.

[0042] Example 8 This embodiment relates to a method for preparing an intrauterine anti-adhesion gel. The difference between this embodiment and Example 1 is that 4arm-PEG-SG is replaced with 4arm-PEG-SC.

[0043] Example 9 This embodiment relates to a method for preparing an intrauterine anti-adhesion gel. The difference between this embodiment and embodiment 1 is that the amount of the chitosan derivative is increased to 0.23 g.

[0044] Example 10 This embodiment relates to a method for preparing an intrauterine anti-adhesion gel. The difference between this embodiment and embodiment 1 is that the amount of polyethylene glycol active ester is increased to 26 mg.

[0045] Embodiment 11 This embodiment relates to a method for preparing an intrauterine anti-adhesion gel. The difference between this embodiment and embodiment 1 is that the gelling conditions are increased from room temperature to 35-40°C.

[0046] Example 12: Comparative Example This embodiment relates to a method for preparing an intrauterine adhesion-preventing gel, comprising the following steps: accurately weighing 0.05 g of 4arm-PEG-SG into a sample bottle, adding 1.00 g of deionized water to fully dissolve polyethylene glycol, and marking it as component A; accurately weighing 0.09 g of a 50 wt% PEI aqueous solution into a sample bottle, adding 9.65 g of deionized water, mixing and dispersing, shaking, and setting aside, and marking it as component B. Take two 1.0 mL syringes, draw 0.5 mL of component A and 0.5 mL of component B into the two syringes respectively, and fully mix the two components through the two-way tube of the syringe to obtain the anti-intrauterine adhesion hydrogel.

[0047] Test example (1) Hydrogel degradation in vitro Using the method of preparing the hydrogels in Examples 1 to 12, 0.5 mL of the hydrogels were prepared in 10 mL centrifuge tubes, 25.0 mL of PBS aqueous solution were added, and the centrifuge tubes were placed in a constant temperature shaking water bath at 37°C and a speed of 100 rpm / min for in vitro degradation experiments, and an equal volume of PBS aqueous solution was replaced every 24 hours. The results of the in vitro degradation experiments are shown in Table 1.

[0048] Table 1 Results of in vitro degradation experiments of hydrogels It can be concluded from Table 1 that the degradation time of the hydrogel prepared with the participation of PEI, gelatin and polyethylene glycol polymer with active ester is faster than the degradation time of chitosan and polyethylene glycol polymer with active ester.

[0049] (2) Hydrogel degradation in the uterine cavity of SD rats The method for preparing the hydrogel in Example 1 was adopted. After 15-25 minutes of mixing component A and component B into gel, the rat was anesthetized with isoflurane, the uterus was surgically opened, and 150 μL of the hydrogel was injected into the uterine cavity of the SD rat through a shield needle. The injection was stopped after the entire uterine cavity was observed to be full, and then the wound was sutured to observe the degradation of the hydrogel in the uterine cavity of the SD rat. The results observed are shown in Figure 2 shown.

[0050] Depend on Figure 2 It can be concluded that the hydrogel prepared in Example 1 will not degrade until 4 days in the uterine cavity of SD rats. After degradation, the appearance and state of the uterus of SD rats are almost the same as those of the uterus of SD rats that have not been injected with hydrogel.

[0051] (3) Scanning electron microscopy The scanning electron microscopy images of the freeze-dried hydrogels prepared in Example 1 and Example 6 were respectively tested, and the results are as follows: Figure 3 shown.

[0052] Depend on Figure 3 It can be concluded that the hydrogels prepared in Example 1 and Example 6 have smooth surfaces after freeze-drying.

[0053] (4) Uterine H&E section The hydrogel prepared in Example 1 was injected into the uterine cavity of SD rats, and H&E sections of the uterus were taken at 1, 3, 7, 14 and 21 days after injection. In order to observe whether the uterine sections of SD rats had inflammation, a blank group (SD rat uterus was not treated in any way) and a control group (SD rat uterus was injected with normal saline) were set up to observe the conditions of the uterine sections of SD rats. The results are as follows: Figure 4 shown.

[0054] Depend on Figure 4 It can be seen that compared with the blank group, no obvious inflammation was found in the uterine sections of SD rats in the control group and the experimental group.

[0055] (5) Shear viscosity test The shear viscosity of the hydrogel prepared in Example 1 was tested by a rotational rheometer. The test results are as follows: Figure 7 shown.

[0056] Depend on Figure 5 It can be concluded that the shear viscosity of the hydrogel prepared in Example 1 gradually decreases with the increase of the shear rate, and the initial shear viscosity of the hydrogel is the largest, with a maximum value of 1926 Pa·s.

[0057] (6) Cytotoxicity Take 5 mg of the anti-intrauterine adhesion hydrogel prepared in Example 1 in a centrifuge tube, irradiate under ultraviolet light for 30 minutes, add 50 ml of complete culture medium, and place in a 4°C refrigerator for 6 hours. After the extraction, filter the extract with a 0.22 μm bacterial filter for subsequent use. L929 cells were incubated in culture media with concentrations of 0 mg / L (control group), 1 mg / L, 10 mg / L and 100 mg / L of the prepared anti-intrauterine adhesion hydrogel extract for 24 hours and 48 hours, and the cell survival rate was observed by CCK-8 experiment. The results are as follows Figure 6 shown.

[0058] Depend on Figure 6 It can be concluded that when L929 cells were cultured in the above-mentioned different concentrations of extract (0 mg / L, 1 mg / L, 10 mg / L and 100 mg / L) for 24 h and 48 h, the average survival rates of the cells were 100.00%, 99.91%, 99.87%, 100.00% and 100.00%, 97.42%, 92.08%, 84.36%, respectively. The experiment proved that the anti-intrauterine adhesion hydrogel has low toxicity.

[0059] (7) Degradation experiment Accurately weigh five portions of 242 mg of the anti-intrauterine adhesion hydrogel prepared in Example 1 into a 50 mL centrifuge tube, add 100-120 times the volume of a PBS aqueous solution with a pH value of about 7.4, and place each of the centrifuge tubes in a constant temperature shaking water bath at 37°C and a shaking speed of 150 rpm / min. Shake to degrade, and record the mass of the anti-intrauterine adhesion hydrogel every 24 hours. Before weighing, filter paper needs to be used to absorb the moisture on the surface of the hydrogel. The results are as follows: Figure 7 shown.

[0060] Depend on Figure 7 It can be concluded that the intrauterine anti-adhesion hydrogel reaches saturation in water absorption after 24 hours of in vitro degradation, and begins to degrade after maintaining this water absorption multiple for 48 hours, and is completely degraded after 192 hours (8 days) of degradation.

[0061] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0062] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A uterine cavity anti-adhesion gel, characterized in that: The raw materials of the gel include: polyethylene glycol high molecular polymer with active ester and amino high molecular polymer, and the mass ratio of the polyethylene glycol high molecular polymer with active ester to the amino high molecular polymer is 1:(0.2-20).

2. The intrauterine anti-adhesion gel according to claim 1, characterized in that: The gel is a three-dimensional network structure formed by cross-linking the polyethylene glycol high molecular polymer with active ester and the amino high molecular polymer.

3. The intrauterine anti-adhesion gel according to claim 1, characterized in that: The solid content of the gel is 1wt%-30wt%.

4. The intrauterine anti-adhesion gel according to any one of claims 1 to 3, characterized in that: The polyethylene glycol high molecular polymer with active ester includes at least one of two-arm polyethylene glycol, four-arm polyethylene glycol and eight-arm polyethylene glycol.

5. The intrauterine anti-adhesion gel according to any one of claims 1 to 3, characterized in that: The amino high molecular polymer includes at least one of gelatin, polypeptide, chitosan, carboxymethyl chitosan, polyethylene imine and branched polyethylene imine.

6. A method for preparing an intrauterine anti-adhesion gel according to any one of claims 1 to 5, characterized in that: The method comprises the following steps: dissolving a polyethylene glycol high molecular polymer with active ester in a solvent to obtain component A; dissolving an amino high molecular polymer in a solvent to obtain component B; and mixing the component A and the component B.

7. The method for preparing the intrauterine anti-adhesion gel according to claim 6, characterized in that: The solvent in component A is at least one of double distilled water, ultrapure water, deionized water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution; the solvent in component B is at least one of double distilled water, ultrapure water, deionized water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution.

8. The method for preparing the intrauterine anti-adhesion gel according to claim 6, characterized in that: The mass concentration of the polyethylene glycol high molecular polymer with active ester in the component A is 0.1wt%-20wt%; the mass concentration of the amino high molecular polymer in the component B is 0.01wt%-30wt%; the volume ratio of the component A to the component B is 1:1-5.

9. The method for preparing the intrauterine anti-adhesion gel according to claim 8, characterized in that: The mass concentration of the polyethylene glycol high molecular polymer with active ester in component A is 0.5wt%-15wt%; the mass concentration of the amino high molecular polymer in component B is 0.05wt%-10wt%.

10. Use of the intrauterine anti-adhesion gel according to any one of claims 1 to 5 in the preparation of a product for preventing intrauterine adhesion.

Citation Information

Cited By

  • Chitosan gel loaded with itraconazole as well as preparation method and application of chitosan gel

    CN120168392A

  • Safe intrauterine adhesion prevention support and use method thereof

    CN122005159A